News
-
-
PRESS RELEASE
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE announces FDA's suspension of IXCHIQ® chikungunya vaccine license in the U.S. due to serious adverse events, despite reported cases consistent with clinical trials. Sales impact to be evaluated -
-
PRESS RELEASE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has published a research update on Valneva SE, maintaining their BUY rating and EUR 8.10 price target, following better-than-expected Q2/25 results and positive outlook on vaccines -
-
-
-
-
-
PRESS RELEASE
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Valneva announces FDA's removal of recommended pause on Chikungunya Vaccine IXCHIQ® in elderly individuals and updates to the Prescribing Information, following EMA's recommendation. Updates reflect Serious Adverse Events and expanded Warnings and Precaution section
